P&G 2019 Citizenship Report Highlights Commitment to Community Impact, Gender Equality, Diversity & Inclusion and Sustainability
The Procter & Gamble Company (NYSE:PG) today released its 2019 Citizenship Report, detailing progress in its Citizenship focus areas of Community Impact, Diversity & Inclusion, Gender Equality and Environmental Sustainability built on the foundation of Ethics and Corporate Responsibility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191202005577/en/
P&G released its 2019 Citizenship Report, detailing progress in its Citizenship focus areas of Community Impact, Diversity & Inclusion, Gender Equality and Environmental Sustainability built on the foundation of Ethics and Corporate Responsibility. (Photo: Business Wire)
From reaching its 2020 goal of providing 15 billion liters of clean water through its Children’s Safe Drinking Water (CSDW) Program, to using its voice to spark conversations about gender and racial equality, 2019 was a year in which P&G’s leadership made a meaningful impact in the community and with the Company’s employees.
“We’ve built Citizenship into our business, and it’s not only doing good, it’s building trust and equity with consumers, and driving growth and value creation—allowing us to be a force for good and a force for growth,” said David Taylor, P&G’s Chairman of the Board, President and Chief Executive Officer. “It’s not a separate thing we do on the side—it’s how we do business every day around the world.”
With operations in about 70 countries serving nearly five billion people, the Company leverages its scale, innovation and talented employees, along with the reach of its 65 leadership brands, to do good every day. P&G’s contributions have been recognized externally with higher 2019 rankings on Fortune’s World’s Most Admired Companies and the Axios Harris Poll 100.
In addition, more than 80% of P&G’s employees expressed a favorable opinion about the Company’s Citizenship efforts, making Citizenship a high-scoring index in the Company’s 2019 annual survey.
Highlights of the P&G 2019 Citizenship Report include:
- Community Impact: P&G provided disaster relief kits filled with its products to families affected by more than 25 natural disasters including wildfires and hurricanes that devastated parts of the U.S., flooding in the Indian state of Kerala, and the deadly earthquake and tsunami that hit Indonesia. Additionally, the Company, through its CSDW Program, made a new commitment to delivering 25 billion liters of clean drinking water by 2025.
- Diversity & Inclusion: P&G was a platinum sponsor of World Pride in New York with 50 sites around the world showing support through various Pride activities. The Company launched “The Look,” the sequel to the Emmy Award-winning film “The Talk,” to continue the conversation about racial bias. P&G also established neurodiversity programs at four Company sites to provide opportunities for individuals on the autism spectrum.
- Gender Equality: Well on the way to P&G’s goal of 50/50 representation at all levels, the Company’s senior leadership team and Board of Directors are now composed of more than 40 percent women. P&G’s Always brand launched its #EndPeriodPoverty Campaign to help keep girls in school, and Secret donated more than $500,000 as part of the brand’s ongoing support for the U.S. Women’s National Soccer Team’s fight for equal pay.
- Environmental Responsibility: In April, the Company marked its one-year anniversary of Ambition 2030 – a set of bold sustainability goals encompassing P&G’s brands, supply chain, society and employees. P&G also partnered with TerraCycle to introduce the “milkman” concept of reusable packaging with Loop. Along with many steps the Company is taking to help solve the global issue of plastic waste, it joined forces with more than 40 companies to form the Alliance to End Plastic Waste and committed to reduce global use of virgin petroleum plastic in product packaging by 50% by 2030.
This is the 20th consecutive year P&G has issued a report on the Company’s efforts to have a positive impact on the world, beginning with P&G’s first Sustainability Report in 1999. The Executive Summary , a 24-page overview of the progress and stories, is available online as well as a 140+ page detailed version of the report .
About Procter & Gamble
P&G serves consumers around the world with one of the strongest portfolios of trusted, quality, leadership brands, including Always®, Ambi Pur®, Ariel®, Bounty®, Charmin®, Crest®, Dawn®, Downy®, Fairy®, Febreze®, Gain®, Gillette®, Head & Shoulders®, Lenor®, Olay®, Oral-B®, Pampers®, Pantene®, SK-II®, Tide®, Vicks®, and Whisper®. The P&G community includes operations in approximately 70 countries worldwide. Please visit http://www.pg.com for the latest news and information about P&G and its brands.
Julie deSylva, Global Company Communications
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kite Announces Long-term Data From ZUMA-1 Showing Approximately Half of Refractory Large B-cell Lymphoma Patients Were Alive Three Years After Yescarta Treatment7.12.2019 22:00:00 EET | Press release
Kite, a Gilead Company (Nasdaq: GILD), today announced new data from the ZUMA-1 trial of Yescarta® (axicabtagene ciloleucel) in adult patients with refractory large B-cell lymphoma. These results included updated overall survival data from the pivotal phase 2 study after three years following a single infusion of Yescarta, as well as an analysis from a separate safety management cohort of patients receiving early steroid intervention for cytokine release syndrome (CRS) and neurologic events. The data were presented today at the 61st American Society of Hematology (ASH) Annual Meeting & Exposition, in Orlando from December 7–10, 2019. With a minimum follow-up of three years after a single infusion of Yescarta (median follow-up of 39.1 months), approximately half (n=47/101; 47 percent) of patients with refractory large B-cell lymphoma in ZUMA-1 pivotal phase 2 cohorts were alive, and the median overall survival (OS) was 25.8 months. These updated three-year survival data were presented a
Janssen Presents Initial Results for BCMA CAR-T Therapy JNJ-4528 Showing Early, Deep and High Responses in the Treatment of Relapsed or Refractory Multiple Myeloma7.12.2019 18:20:00 EET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today initial results from the Phase 1b/2 CARTITUDE-1 study (NCT03548207) evaluating the efficacy and safety of JNJ-68284528 (JNJ-4528), an investigational B cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell (CAR-T) therapy being evaluated in the treatment of patients with relapsed or refractory multiple myeloma. The study enrolled patients who had received at least three prior lines of therapy or were double refractory to a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD); had received a PI, IMiD and an anti-CD38 antibody. The CARTITUDE-1 study results, premiered at the American Society of Hematology (ASH) Annual Meeting, were featured as an oral presentation and highlighted in the official ASH press programme (Abstract #577).1 Results from the Phase 1b portion of the CARTITUDE-1 study showed early and deep responses among patients (n=29) with a median of five prior multiple myeloma
Imbruvica®▼(ibrutinib) Combination Therapy Data From Two Studies and Long-Term Integrated Analysis Presented at ASH 2019 Show Efficacy and Safety in First-Line Treatment of Chronic Lymphocytic Leukaemia7.12.2019 18:18:00 EET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced combination data from two studies and a long-term integrated analysis evaluating the use of Imbruvica® (ibrutinib) for the treatment of previously untreated patients with CLL. Results from a 48-month follow-up analysis of the Phase 3 E1912 clinical study reported a statistically significant difference in PFS and OS for ibrutinib plus rituximab compared to a standard chemoimmunotherapy regimen of FCR.1 Further, the latest integrated analysis from the Phase 3 RESONATETM (PCYC-1112) and RESONATETM-2 (PCYC-1115/1116) studies investigating the use of single-agent ibrutinib in CLL, reported at up to six years of follow-up, PFS, OS and response rates improved when ibrutinib was used in earlier lines of therapy.2 During this extended follow-up, ibrutinib was tolerated across all lines of therapy with 19 percent of patients discontinuing due to adverse events.2 In addition, results presented from the Phase 2 CAPTIVATE stu
Takeda to Present Results from the Phase 3 TOURMALINE-AL1 Trial of NINLARO in Patients with Amyloidosis7.12.2019 17:30:00 EET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced that results of the TOURMALINE-AL1 trial will be presented during an oral session at the 61st American Society of Hematology (ASH) annual meeting on Saturday, December 7, 2019 in Orlando, Florida. TOURMALINE-AL1 is a Phase 3, randomized clinical trial evaluating the effect of NINLAROTM (ixazomib) in combination with dexamethasone in patients with relapsed or refractory systemic light-chain (AL) amyloidosis. The TOURMALINE-AL1 trial did not meet the first of the two primary endpoints of significant improvement in overall hematologic response, as reported in June 2019. Hematologic responses were seen in 53% versus 51% of patients receiving NINLARO plus dexamethasone versus physician’s choice (odds ratio 1.10 [95% CI 0.60-2.01], p=0.762) as assessed by an Adjudication Committee (AC). The second primary endpoint of two-year vital organ deterioration or death was not mature at the time of analysis. Other endpoints stu
Schlumberger Announces Fourth-Quarter and Full-Year 2019 Results Conference Call6.12.2019 21:07:00 EET | Press release
Schlumberger Limited (NYSE:SLB) will hold a conference call on January 17, 2020 to discuss the results for the fourth quarter and full year ending December 31, 2019. The conference call is scheduled to begin at 8:30 am US Eastern time and a press release regarding the results will be issued at 7:00 am US Eastern time. To access the conference call, listeners should contact the Conference Call Operator at +1 (844) 721-7241 within North America or +1 (409) 207-6955 outside of North America approximately 10 minutes prior to the start of the call and the access code is 4013483. A webcast of the conference call will be broadcast simultaneously at www.slb.com/irwebcast on a listen-only basis. Listeners should log in 15 minutes prior to the start of the call to test their browsers and register for the webcast. Following the end of the conference call, a replay will be available at www.slb.com/irwebcast until February 17, 2020, and can be accessed by dialing +1 (866) 207-1041 within North Amer
BUFF STUDIO Globally Launches My Coloring, a Mobile 3D Pixel Art Coloring Book Game6.12.2019 16:00:00 EET | Press release
BUFF STUDIO announced on December 5 that it launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191206005162/en/ BUFF STUDIO launched My Coloring, a mobile 3D pixel art coloring book game, in 155 countries simultaneously. My Coloring is a game that materializes a 3D pixel art coloring book on mobile devices. You can blow your stress away as you paint spaces in the order of numbers on the screen while reading calming messages. Relaxing background music you will listen during gameplay and its fairytale-like design will give you pleasure and happiness. You can download it for free on Google Play and the Apple App Store. (Graphic: Business Wire) Its Android and iOS versions were released at the same time so the users can download it for free on Google Play and the Apple App Store. My Coloring is a game that materializes a 3D pixel art col
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom